Literature DB >> 1735557

DNA polymorphism of HLA class II genes in primary biliary cirrhosis.

N Morling1, K Dalhoff, L Fugger, J Georgsen, B Jakobsen, L Ranek, N Odum, A Svejgaard.   

Abstract

We investigated the DNA restriction fragment length polymorphism of the major histocompatibility complex class II genes: HLA-DRB, -DQA, -DQB, DPA, -DPB, the serologically defined HLA-A, B, C, DR antigens, and the primed lymphocyte typing defined HLA-DP antigens in 23 Danish patients with primary biliary cirrhosis (PBC) and in healthy Danes. The following genetic markers were found with increased frequencies in PBC: HLA-B8 (relative risk, RR = 2.4, P less than 0.05, 'corrected' P greater than 0.05), HLA-DR3 (RR = 3.4, P less than 0.01, 'corrected' P less than 0.05), the DRB3*01/02/03 (DRw52) associated DRB Bgl II 9.1 kilobase (kb) fragment (RR = 2.9; P less than 0.05, 'corrected' P greater than 0.05), the DQA1*0501 associated DQA Taq I 4.8 kb fragment (RR = 3.1; P less than 0.05, 'corrected' P greater than 0.05), the DQB1*0201 (DQw2) associated DQB Hin dIII 11.5 kb fragment (RR = 3.1; P less than 0.05, 'corrected' P greater than 0.05). No DNA fragments specific for DRB1*0301 (DR3) could be identified. The frequencies in PBC of other genetic markers including DRw8, DRB1*08, HLA-DP antigens, DPA, and DPB genes did not differ significantly from those in controls. The associations between PBC and B8, DR3, DQA1*0501, and DQB1*0201, which are frequently found together on the same haplotype, are at variance with recent reports on associations between PBC and Drw8. The discrepancy suggests that PBC is genetically heterogenous.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735557     DOI: 10.1007/bf00189520

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  23 in total

1.  Possible correlation of TNF alpha-production with -RFLP in humans.

Authors:  L Fugger; K Bendtzen; N Morling; L Ryder; A Svejgaard
Journal:  Eur J Haematol       Date:  1989-09       Impact factor: 2.997

2.  Association of primary sclerosing cholangitis with HLA-DRw52a.

Authors:  E J Prochazka; P I Terasaki; M S Park; L I Goldstein; R W Busuttil
Journal:  N Engl J Med       Date:  1990-06-28       Impact factor: 91.245

3.  The HLA-DP polymorphism in Denmark investigated by local and international PLT reagents. Definition of two "new" DP antigens.

Authors:  N Odum; R Hartzman; B K Jakobsen; N Morling; P Platz; F M Robbins; L P Ryder; A Svejgaard
Journal:  Tissue Antigens       Date:  1986-08

4.  HLA-DR antigens in primary biliary cirrhosis: lack of association.

Authors:  M F Bassendine; P J Dewar; O F James
Journal:  Gut       Date:  1985-06       Impact factor: 23.059

5.  Restriction fragment length polymorphism of the HLA-DP subregion and correlations to HLA-DP phenotypes.

Authors:  J J Hyldig-Nielsen; N Morling; N Odum; L P Ryder; P Platz; B Jakobsen; A Svejgaard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

6.  Restriction fragment length polymorphism of two HLA-B-associated transcripts genes in five autoimmune diseases.

Authors:  L Fugger; N Morling; L P Ryder; B K Jakobsen; V Andersen; P Oxholm; K Dalhoff; C Heilmann; F Karup Pedersen; J Friis
Journal:  Hum Immunol       Date:  1991-01       Impact factor: 2.850

7.  HLA-DR phenotype and HLA-B,DR haplotype frequencies in 704 unrelated Danes.

Authors:  B K Jakobsen; N Morling; P Platz; L P Ryder; M Thomsen; A Svejgaard
Journal:  Tissue Antigens       Date:  1981-10

8.  NcoI restriction fragment length polymorphism (RFLP) of the tumour necrosis factor (TNF alpha) region in primary biliary cirrhosis and in healthy Danes.

Authors:  L Fugger; N Morling; L P Ryder; P Platz; J Georgsen; B K Jakobsen; A Svejgaard; K Dalhoff; L Ranek
Journal:  Scand J Immunol       Date:  1989-08       Impact factor: 3.487

9.  Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide.

Authors:  K Bendtzen; N Morling; A Fomsgaard; M Svenson; B Jakobsen; N Odum; A Svejgaard
Journal:  Scand J Immunol       Date:  1988-11       Impact factor: 3.487

10.  Primary biliary cirrhosis associated with HLA-DRw3.

Authors:  G Ercilla; A Parés; F Arriaga; M Bruguera; R Castillo; J Rodés; J Vives
Journal:  Tissue Antigens       Date:  1979-11
View more
  7 in total

Review 1.  Genetics and genomics of primary biliary cirrhosis.

Authors:  Brian D Juran; Konstantinos N Lazaridis
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

Review 2.  Human leukocyte antigen in primary biliary cirrhosis: an old story now reviving.

Authors:  Pietro Invernizzi
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

3.  Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.

Authors:  Jennifer E Guy; Peiqing Qian; Jeffrey A Lowell; Marion G Peters
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

4.  Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia.

Authors:  Maria Grazia Clemente; Fulvia Frau; Matilde Bernasconi; Maria Doloretta Macis; Lucia Cicotto; Giampaolo Pilleri; Stefano De Virgiliis; Paolo Castiglia; Patrizia Farci
Journal:  United European Gastroenterol J       Date:  2016-08-09       Impact factor: 4.623

5.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

Review 6.  New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.

Authors:  Giacomo Mulinacci; Andrea Palermo; Alessio Gerussi; Rosanna Asselta; Merrill Eric Gershwin; Pietro Invernizzi
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

Review 7.  Association of human leukocyte antigen class II with susceptibility to primary biliary cirrhosis: a systematic review and meta-analysis.

Authors:  Baodong Qin; Jiaqi Wang; Jia Chen; Yan Liang; Zaixing Yang; Renqian Zhong
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.